Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study
Autor: | Irene Iglesias-Peinado, Ana Herranz-Alonso, RM Romero-Jiménez, Almudena Ribed, Roberto Collado-Borrell, María Sanjurjo-Sáez, Maite Martin-Conde, Vicente Escudero-Vilaplana, Cristina Gonzalez-Anleo |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
020205 medical informatics Health Informatics 02 engineering and technology smartphone Health outcomes 03 medical and health sciences 0302 clinical medicine Patient satisfaction Quality of life Neoplasms Internal medicine Intervention (counseling) Health care 0202 electrical engineering electronic engineering information engineering medicine Humans e-OncoSalud oral antineoplastic agent Adverse effect app Original Paper business.industry Mobile apps Cancer medicine.disease Mobile Applications Patient Satisfaction 030220 oncology & carcinogenesis oncology Quality of Life business Follow-Up Studies |
Zdroj: | JMIR mHealth and uHealth |
ISSN: | 2291-5222 |
Popis: | Background Oral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care. Objective The primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objectives were to analyze the role of the app in communication with health care professionals and patient satisfaction with the app. Methods We performed a comparative, quasi-experimental study based on a prepost intervention with 101 patients (control group, n=51, traditional pharmacotherapeutic follow-up vs intervention group, n=50, follow-up through e-OncoSalud, a custom-designed app that promotes follow-up at home and the safety of patients receiving OAAs). The effect of this app on drug safety, adherence to treatment, and quality of life was evaluated. Results With regard to drug safety, 73% (37/51) of the patients in the control group and 70% (35/50) of the patients in the intervention group (P=.01) presented with drug-related problems. The probability of detecting an insufficiently treated health problem in the intervention group was significantly higher than that in the control group (P=.04). The proportion of patients who presented with side effects in the intervention group was significantly lower than that in the control group (P>.99). In the control group, 49% (25/51) of the patients consumed some health resources during the first 6 months of treatment compared with 36% (18/50) of the patients in the intervention group (P=.76). Adherence to treatment was 97.6% (SD 7.9) in the intervention group, which was significantly higher than that in the control group (92.9% [SD 10.0]; P=.02). The EuroQol-5D in the intervention group yielded a mean (SD) index of 0.875 (0.156), which was significantly higher than that in the control group (0.741 [0.177]; P Conclusions Use of e-OncoSalud for the real-time follow-up of patients receiving OAAs facilitated the optimization of some health outcomes. The intervention group had significantly higher health-related quality of life and adherence to treatment than the control group. Further, the probability of the intervention group presenting with side effects was significantly lower than that of the control group. |
Databáze: | OpenAIRE |
Externí odkaz: |